Monday, October 23, 2023
12:00PM – 1:00PM ET
Please note this TeleECHO program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
|Michael R. Grunwald, MD, FACP
Chief, Leukemia Division
Director, Transplantation and Cellular Therapy Program
Levine Cancer Institute, Atrium Health
Clinical Associate Professor, Wake Forest School of Medicine
This activity will explore the management of patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) through a series of live-virtual TeleECHO programs, each comprising didactic slide review, case study discussion, and a robust Q&A session. This program will address the role of genetic and molecular markers in treatment selection as well as best practices for treatment of newly diagnosed, relapsed/refractory, and secondary AML. A summary of approaches to treatment-related adverse event recognition and mitigation will also be discussed.
This educational activity is intended for U.S.-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with AML.
Upon the completion of this program, attendees should be able to:
- Appraise current data concerning molecular and genetic markers to inform therapeutic decision-making in AML
- Describe the latest strategies for management of newly diagnosed and relapsed/refractory AML as informed by patient-specific features
- Assess current data concerning management of adverse events and implementation of shared decision-making to implement therapy in AML
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]